Company

Microvascular Therapeutics

Biotechnology Research Tucson, Arizona, United States 13 employees

Employees: 13
Contacts: 3
Emails: 3
Phones: 2

mvtpharma.com LinkedIn Crunchbase

Microvascular Therapeutics Overview

Headquarters: Tucson, Arizona, United States
Website: mvtpharma.com
Industry: Biotechnology Research
Employees: 13
Founded: 2009
Funding: 4.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Ultrasound contrast agent theranostics imaging vascular thrombosis

About Microvascular Therapeutics

Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity®, the world’s #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway.

Microvascular Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 2; 50.0% coverage

Microvascular Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Evan Unger, M.d.	Founder and CEO of Microvascular Therapeutics - ⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀ ⠀ Co-founder and Executive Chairman		View
Emmanuelle J. Meuillet	Chief Operating and Scientific Officer at Microvascular Therapeutics	Greater Tucson Area, United States	Email Phone
Marty Rosenberg		Denville, New Jersey, United States	Email
Thom Tulip		Andover, Massachusetts, United States	Email Phone